Perfuse Therapeutics

Bayer | Pharmaceuticals to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline https://lnkd.in/d6SPTZka

We are excited to share Bayer | Pharmaceuticals intent to acquire Perfuse Therapeutics!!

Prevent Blindness has declared February Age-related Macular Degeneration (AMD) and Low Vision Month to provide the public and professionals with education and various expert-approved resources. Ophthalmology Innovation Source highlighted a recent presentation by Perfuse Therapeutics. Targeting Retinal Ischemia: A New Approach from Perfuse Therapeutics Retinal ischemia and impaired blood flow are increasingly recognized as key drivers of vision loss across multiple retinal diseases. In this video from OIS XV, Sevgi Gurkan, MD, founder, president, and CEO of Perfuse Therapeutics, discusses the company’s approach to addressing retinal disease by targeting ischemia and neurodegeneration earlier in the disease process. Gurkan explains the clinical observations that led to the founding of Perfuse Therapeutics and provides an overview of the company’s lead program, which is designed to restore physiologic blood flow to ischemic retinal tissue rather than targeting VEGF or inflammation directly. She also outlines the potential for this strategy to be applied across multiple retinal indications and to complement existing therapies as the program advances into clinical development. Watch here-> https://lnkd.in/gedAvZ4k

Thrilled to share that our CEO, Sevgi Gurkan, MD will be presenting at OIS XV in San Diego on Nov 21–22. We are grateful for the chance to connect with the Ophthalmology Innovation Source (OIS) community and showcase our investigational drug PER-001 in Glaucoma & Diabetic Retinopathy. OIS is a trusted community where ideas take root, partnerships are born, and the future of ophthalmology is shaped. See you there! #OISXV #Ophthalmology #EyeCare #Innovation

🚀 Exciting Announcement from Perfuse Therapeutics! 🚀 We are thrilled to share that our Chief Medical Officer, Dr. Phillip Lai, will be presenting data on PER-001 at Eyecelerator @ AAO 2025, held at the Orange County Convention Center in Orlando, FL on October 16th. PER-001 represents a potential revolutionary advancement as a first-in-class endothelin antagonist in a bio-erodible intravitreal implant, offering every 6-month dosing. It holds the promise to become the first disease-modifying treatment for primary open-angle glaucoma (POAG) and diabetic retinopathy (DR). Initial findings show that PER-001 is well tolerated, safe, and significantly improves both function and structure. We look forward to sharing more details at the event and connecting with other industry leaders and innovators. #PerfuseTherapeutics #Ophthalmology #Glaucoma #DiabeticRetinopathy #Eyecelerator2025

Thrilled to share that Dr. Phillip Lai, Chief Medical Officer of Perfuse Therapeutics, presented PER-001 glaucoma data at ISER 2025 in Atlanta this week. PER-001 demonstrated significant visual and structural improvements in glaucoma along with a favorable safety profile, highlighting its potential as a disease-modifying treatment. Energized by the incredible science and engaging discussions at the meeting. Looking forward to future advancements in ophthalmology! #glaucoma #ophthalmology #ISER2025

Please listen to Dr. Singer’s interview with Dr. Khanani, in Retinal Physician. They discuss how PER-001 for the first time in diabetic retinopathy demonstrates not only structural but also functional improvements. Listen here: https://lnkd.in/eXzma5Kt

Perfuse Therapeutics is excited to share a video featuring Arshad M. Khanani, MD, MA, FASRS, discussing how our investigational drug, PER-001, offers a novel mechanism of action for treating diabetic retinopathy. At the recent American Society of Retina Specialists' annual meeting, Dr. Khanani highlights the potential of PER-001, an endothelin antagonist, in advancing diabetic retinopathy therapy. Watch the full video here: https://lnkd.in/enU9xnaZ

In this video, Justis Ehlers, MD, FASRS, a retina surgeon from the Cole Eye Institute at the Cleveland Clinic, shares data showing how PER-001 improved structure and visual function in patients with diabetic retinopathy. Justis Ehlers presented at the 2025 annual meeting of the American Society of Retina Specialists (ASRS). https://lnkd.in/gVtzu9VM

More news coming out of ASRS 2025. Thanks to Denise Myshko for her coverage of Perfuse Therapeutics Phase 2a data on PER-001. https://lnkd.in/eyzc6cMH